StockWatch
·

Concord Drugs Ltd Q1 FY27 Results

CONCORDQ1 FY27 Results
Filing
Result:Good· Market: Flat#Broad based#Margin expansion#Base effect
MetricValue ( Cr)Q4 FY26Q1 FY26
Revenue20.9444.7%53.9%
Total Income20.9544.7%54.0%
Expenditure19.4047.8%44.3%
PBT1.54106.7%874.7%
Net Profit1.11111.0%845.7%
OPM10.90%6.98pp3.43pp
NPM5.32%3.93pp4.45pp
EPS0.8580.8%608.3%
View full financials

Revenue grew a strong 53.9% YoY with OPM expanding ~340bps (7.5%→10.9%) and NPM lifting sharply, but the 845% PAT jump is off a near-breakeven prior-year base, so it's rated good rather than very_good.

Informational and educational content only. Not investment advice.